for Journals by Title or ISSN
for Articles by Keywords
help
Similar Journals
Journal Cover
The Lancet Oncology
Journal Prestige (SJR): 16.085
Citation Impact (citeScore): 10
Number of Followers: 205  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1470-2045 - ISSN (Online) 1474-5488
Published by Elsevier Homepage  [3182 journals]
  • CAR T-cell cocktail therapy for B-cell malignancies
    • Abstract: Publication date: Available online 7 November 2019Source: The Lancet OncologyAuthor(s): Elizabeth Gourd
       
  • New smoking ban for restaurants and bars in Austria
    • Abstract: Publication date: Available online 7 November 2019Source: The Lancet OncologyAuthor(s): Talha Khan Burki
       
  • Presenting symptoms of cancer and stage at diagnosis: evidence from a
           cross-sectional, population-based study
    • Abstract: Publication date: Available online 6 November 2019Source: The Lancet OncologyAuthor(s): Minjoung Monica Koo, Ruth Swann, Sean McPhail, Gary A Abel, Lucy Elliss-Brookes, Greg P Rubin, Georgios LyratzopoulosSummaryBackgroundEarly diagnosis interventions such as symptom awareness campaigns increasingly form part of global cancer control strategies. However, these strategies will have little impact in improving cancer outcomes if the targeted symptoms represent advanced stage of disease. Therefore, we aimed to examine associations between common presenting symptoms of cancer and stage at diagnosis.MethodsIn this cross-sectional study, we analysed population-level data from the English National Cancer Diagnosis Audit 2014 for patients aged 25 years and older with one of 12 types of solid tumours (bladder, breast, colon, endometrial, laryngeal, lung, melanoma, oral or oropharyngeal, ovarian, prostate, rectal, and renal cancer). We considered 20 common presenting symptoms and examined their associations with stage at diagnosis (TNM stage IV vs stage I–III) using logistic regression. For each symptom, we estimated these associations when reported as a single presenting symptom and when reported together with other symptoms.FindingsWe analysed data for 7997 patients. The proportion of patients diagnosed with stage IV cancer varied substantially by presenting symptom, from 1% (95% CI 1–3; eight of 584 patients) for abnormal mole to 80% (71–87; 84 of 105 patients) for neck lump. Three of the examined symptoms (neck lump, chest pain, and back pain) were consistently associated with increased odds of stage IV cancer, whether reported alone or with other symptoms, whereas the opposite was true for abnormal mole, breast lump, postmenopausal bleeding, and rectal bleeding. For 13 of the 20 symptoms (abnormal mole, breast lump, post-menopausal bleeding, rectal bleeding, lower urinary tract symptoms, haematuria, change in bowel habit, hoarseness, fatigue, abdominal pain, lower abdominal pain, weight loss, and the “any other symptom” category), more than 50% of patients were diagnosed at stages other than stage IV; for 19 of the 20 studied symptoms (all except for neck lump), more than a third of patients were diagnosed at stages other than stage IV.InterpretationDespite specific presenting symptoms being more strongly associated with advanced stage at diagnosis than others, for most symptoms, large proportions of patients are diagnosed at stages other than stage IV. These findings provide support for early diagnosis interventions targeting common cancer symptoms, countering concerns that they might be simply expediting the detection of advanced stage disease.FundingUK Department of Health's Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis; and Cancer Research UK.
       
  • Earlier diagnosis: the importance of cancer symptoms
    • Abstract: Publication date: Available online 6 November 2019Source: The Lancet OncologyAuthor(s): Katriina Whitaker
       
  • Denosumab for giant cell tumour of bone: success and limitations
    • Abstract: Publication date: Available online 6 November 2019Source: The Lancet OncologyAuthor(s): John H Healey
       
  • Developing an independent Palestinian cancer care capacity
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Ziv Gil, Fadi Atrash, Suliman Za'aroura, Salem Billan, Walid Nammour
       
  • Gingival localisation of extramedullary multiple myeloma
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Niccolò Lombardi, Andrea Flora, Roberto Franchini, Daniela Sorrentino, Giovanni Lodi, Elena M Varoni
       
  • 5-year outcome after complete mesocolic excision for right-sided colon
           cancer: a population-based cohort study
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Claus A Bertelsen, Anders U Neuenschwander, Jens E Jansen, Jutaka R Tenma, Michael Wilhelmsen, Anders Kirkegaard-Klitbo, Else R Iversen, Birgitte Bols, Peter Ingeholm, Leif A Rasmussen, Lars V Jepsen, Pernille W Born, Bent Kristensen, Jakob KleifSummaryBackgroundThe benefits of extensive lymph node dissection as performed in complete mesocolic excision are still debated, although recent studies have shown an association with improved long-term outcomes. However, none of these studies had an intention-to-treat design or aimed to show a causal effect; therefore in this study, we aimed to estimate the causal oncological treatment effects of complete mesocolic excision on right-sided colon cancer.MethodsWe did a population-based cohort study involving prospective data collected from four hospitals in Denmark. We compared the oncological outcome data of patients at one centre performing central lymph node dissection and vascular division after almost complete exposure of the proximal part of the superior mesenteric vein (ie, the complete mesocolic excision group) with three other centres performing conventional resections with unstandardised and limited lymph node dissection (ie, non-complete mesocolic excision; control group). We included data for all patients in the Capital Region of Denmark undergoing elective curative-intent right-sided colon resections for stages I–III colon cancer, as categorised by the Union for International Cancer Control (UICC; 5th edition), from June 1, 2008, to Dec 31, 2013. Patients were followed-up for 5·2 years after surgery. The primary outcome was the cumulative incidence of recurrence after 5·2 years of surgery. Inverse probability of treatment weighting and competing risk analyses were used to estimate the possible causal effects of complete mesocolic excision. This study is registered with ClinicalTrials.gov, number NCT03754075.Findings1069 patients (813 in the control group and 256 in the complete mesocolic excision group) underwent curative-intent elective surgery for right-sided colon cancer during the study period. None of the patients were lost to follow-up regarding survival or recurrence status, and consequently no patient was censored in the analyses. The 5·2-year cumulative incidence of recurrence was 9·7% (95% CI 6·3–13·1) in the complete mesocolic excision group compared with 17·9% (15·3–20·5) in the control group, and the absolute risk reduction of complete mesocolic excision after 5·2 years was 8·2% (95% CI 4·0–12·4; p=0·00015). In the control group, 145 (18%) of 813 patients were diagnosed with a recurrence and 281 (35%) died during follow-up, whereas in the complete mesocolic excision group 25 (10%) of 256 patients were diagnosed with a recurrence and 75 (29%) died during follow-up.InterpretationThis study shows a causal treatment effect of central mesocolic lymph node excision on risk of recurrence after resection for right-sided colon adenocarcinoma. Complete mesocolic excision has the potential to reduce the risk of recurrence and improve long-term outcome after resection for all UICC stages I–III of right-sided colon adenocarcinomas.FundingThe Tvergaard Fund, Helen Rude Fund, Krista and Viggo Petersen Fund, Olga Bryde Nielsen Fund, and Else and Mogens Wedell-Wedellsborg Fund.
       
  • Cancer awareness crusades—pink ribbons and growing moustaches
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Giovanni E Cacciamani, Mariana C Stern, Luis G Medina, Karanvir Gill, Rene Sotelo, Inderbir S Gill
       
  • Navigating prostate cancer control in Nigeria
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Runcie C W Chidebe, Charles T Orjiakor, Ian Pereira, Sampson C Ipiankama, David W Lounsbury, Fabio Y Moraes
       
  • Metronomic chemotherapy option for advanced oral cancer
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Elizabeth Gourd
       
  • Correction to Lancet Oncol 2019; 20: e616
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s):
       
  • Correction to Lancet Oncol 2019; 20: e522–34
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s):
       
  • Correction to Lancet Oncol 2019; 20: 1506–517
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s):
       
  • Correction to Lancet Oncol 2019; 20: 1602–14
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s):
       
  • Correction to Lancet Oncol 2019; 20: 1286–94
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s):
       
  • Sparing of swallowing-related organs in radiotherapy for oropharyngeal
           squamous cell carcinoma–Authors’ reply
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): David A Palma, Sylvia Mitchell, Anthony Nichols
       
  • Sparing of swallowing-related organs in radiotherapy for oropharyngeal
           squamous cell carcinoma
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Rosario Mazzola, Michele Rigo, Davide Tomasini, Giuseppe Napoli, Vanessa Figlia, Francesco Ricchetti, Filippo Alongi
       
  • What is the best PET target for early biochemical recurrence of prostate
           cancer'–Authors’ reply
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Jeremie Calais, Francesco Ceci, Matthias Eiber, Thomas A Hope, Michael S Hofman, Christoph Rischpler, Tore Bach-Gansmo, Wolfgang P Fendler, Johannes Czernin
       
  • What is the best PET target for early biochemical recurrence of prostate
           cancer'
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Gerald L Andriole
       
  • Clarifications sought for implications of PORTEC-3 in clinics
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Swaroop Revannasiddaiah, Vinayak V Maka, Santhosh K Devadas
       
  • Moonshot or groundshot: addressing Europe's cancer challenge through a
           patient-focused, data-enabled lens
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Mark Lawler, Peter Naredi, Tanja Cufer, Ian Banks, Yolande Lievens, Giles Vassal, Matti Aapro, Maja Južnič Sotlar, Thierry Philip, Jacek Jassem, Jana Pelouchova, Françoise Meunier, Richard Sullivan, on behalf of the Lancet Oncology European Groundshot Commission
       
  • Hyperbaric oxygen for radiation cystitis
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): John J Feldmeier
       
  • CDK4/6 inhibitors in breast cancer: a role in triple-negative disease'
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Shom Goel, Sara M Tolaney
       
  • Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): William H Meyer
       
  • Complete mesocolic excision for colon cancer: is now the time for a change
           in practice'
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Nicholas P West
       
  • Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid
           tumours'
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Sumanta Pal, Siwen Hu-Lieskovan, Neeraj Agarwal
       
  • Stereotactic beam radiotherapy for prostate cancer: is less, more'
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Raymond Miralbell
       
  • Quality of life considerations in the treatment of metastatic
           hormone-sensitive prostate cancer
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Suzanne K Chambers, Mark Frydenberg, Jeff Dunn
       
  • Nivolumab for previously treated squamous oesophageal carcinoma
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Elizabeth C Smyth, Florian Lordick
       
  • Global elimination of cervical cancer is achievable—with commitment
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): The Lancet Oncology
       
  • Early intervention effective in smouldering multiple myeloma
    • Abstract: Publication date: Available online 1 November 2019Source: The Lancet OncologyAuthor(s): Elizabeth Gourd
       
  • Core elements of national cancer control plans: a tool to support plan
           development and review
    • Abstract: Publication date: November 2019Source: The Lancet Oncology, Volume 20, Issue 11Author(s): Andrew Oar, Fabio Y Moraes, Yannick Romero, Andre Ilbawi, Mei Ling YapSummaryWhen developed and implemented effectively, national cancer control plans (NCCPs) improve cancer outcomes at the population level. However, many countries do not have a high-quality, operational NCCP, contributing to disparate cancer outcomes globally. Until now, a standard reference of NCCP core elements has not been available to guide development and evaluation across diverse countries and contexts. In this Policy Review, we describe the methods, process, and outcome of an initiative to develop an itemised and evidence-based comprehensive checklist of core elements for NCCP formulation. The final list provides a ready-to-use guide to support NCCP development and to facilitate internal and external critical appraisal of existing NCCPs for countries of all income levels and settings. Governments, policy makers, and stakeholders can utilise this checklist, while considering their own unique contexts and priorities, from the drafting through to the implementation of NCCPs.
       
  • LEEP for cervical neoplasia recurrence in HIV-positive patients
    • Abstract: Publication date: Available online 1 November 2019Source: The Lancet OncologyAuthor(s): Manjulika Das
       
  • Lorlatinib: a new treatment option for ROS1-positive lung cancer
    • Abstract: Publication date: Available online 25 October 2019Source: The Lancet OncologyAuthor(s): Michaël Duruisseaux
       
  • Promising radiotherapy classifier for early breast cancer
    • Abstract: Publication date: Available online 24 October 2019Source: The Lancet OncologyAuthor(s): Manjulika Das
       
  • Endocrine-based therapy versus chemotherapy in advanced breast cancer
    • Abstract: Publication date: Available online 24 October 2019Source: The Lancet OncologyAuthor(s): Marie Robert, Nicholas Turner
       
  • Alleviation of radiotherapy-induced oral mucositis
    • Abstract: Publication date: Available online 24 October 2019Source: The Lancet OncologyAuthor(s): Elizabeth Gourd
       
  • Reducing infection-related morbidity and mortality in patients with
           myeloma
    • Abstract: Publication date: Available online 23 October 2019Source: The Lancet OncologyAuthor(s): Karthik Ramasamy
       
  • Post-operative salvage androgen deprivation and radiotherapy for prostate
           cancer
    • Abstract: Publication date: Available online 16 October 2019Source: The Lancet OncologyAuthor(s): Anthony V D'Amico
       
  • Short-term androgen deprivation therapy combined with radiotherapy as
           salvage treatment after radical prostatectomy for prostate cancer
           (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial
    • Abstract: Publication date: Available online 16 October 2019Source: The Lancet OncologyAuthor(s): Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, Jean-Léon Lagrange, Stéphane Supiot, Yazid Belkacemi, Didier Peiffert, Nedla Allouache, Bernard M Dubray, Stéphanie Servagi-Vernat, Jean-Philippe Suchaud, Gilles Crehange, Stéphane Guerif, Meryem Brihoum, Nicolas Barbier, Pierre Graff-Cailleaud, Alain Ruffion, Sophie DussartSummaryBackgroundRadiotherapy is the standard salvage treatment after radical prostatectomy. To date, the role of androgen deprivation therapy has not been formally shown. In this follow-up study, we aimed to update the results of the GETUG-AFU 16 trial, which assessed the efficacy of radiotherapy plus androgen suppression versus radiotherapy alone.MethodsGETUG-AFU 16 was an open-label, multicentre, phase 3, randomised, controlled trial that enrolled men (aged ≥18 years) with Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed adenocarcinoma of the prostate (but no previous androgen suppression or pelvic radiotherapy), stage pT2, T3, or T4a (bladder neck involvement only) and pN0 or pNx according to the tumour, node, metastasis (TNM) staging system, whose prostate-specific antigen (PSA) concentration increased from 0·1 ng/mL to between 0·2 ng/mL and 2·0 ng/mL after radical prostatectomy, without evidence of clinical disease. Patients were assigned through central randomisation (1:1) to short-term androgen suppression (subcutaneous injection of 10·8 mg goserelin on the first day of irradiation and 3 months later) plus radiotherapy (3D conformal radiotherapy or intensity modulated radiotherapy of 66 Gy in 33 fractions, 5 days a week for 7 weeks) or radiotherapy alone. Randomisation was stratified using a permuted block method (block sizes of two and four) according to investigational site, radiotherapy modality, and prognosis. The primary endpoint was progression-free survival in the intention-to-treat population. This post-hoc one-shot data collection done 4 years after last data cutoff included patients who were alive at the time of the primary analysis and updated long-term patient status by including dates for first local progression, metastatic disease diagnosis, or death (if any of these had occurred) or the date of the last tumour evaluation or last PSA measurement. Survival at 120 months was reported. Late serious adverse effects were assessed. This trial is registered on ClinicalTrials.gov, NCT00423475.FindingsBetween Oct 19, 2006, and March 30, 2010, 743 patients were randomly assigned, 374 to radiotherapy alone and 369 to radiotherapy plus goserelin. At the time of data cutoff (March 12, 2019), the median follow-up was 112 months (IQR 102–123). The 120-month progression-free survival was 64% (95% CI 58–69) for patients treated with radiotherapy plus goserelin and 49% (43–54) for patients treated with radiotherapy alone (hazard ratio 0·54, 0·43–0·68; stratified log-rank test p
       
  • Tumour Treating Fields for mesothelioma: controversy versus opportunity
    • Abstract: Publication date: Available online 15 October 2019Source: The Lancet OncologyAuthor(s): Dean A Fennell
       
  • Targeted therapy for BRAF-mutant colorectal cancer
    • Abstract: Publication date: Available online 10 October 2019Source: The Lancet OncologyAuthor(s): Ashray Gunjur
       
  • Quality of life and CAR-T cell therapy in children, adolescents, and young
           adults with haematological malignancies
    • Abstract: Publication date: Available online 9 October 2019Source: The Lancet OncologyAuthor(s): Fabio Efficace, Marco Vignetti
       
  • Quality of life with durvalumab in stage III non-small-cell lung cancer
    • Abstract: Publication date: Available online 7 October 2019Source: The Lancet OncologyAuthor(s): Amélie Anota, Virginie Westeel
       
  • Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment
           of EGFR-mutated non-small-cell lung cancer'
    • Abstract: Publication date: Available online 4 October 2019Source: The Lancet OncologyAuthor(s): Rafael Rosell, Carlos Pedraz-Valdunciel
       
  • Real-time artificial intelligence for detection of upper gastrointestinal
           cancer by endoscopy: a multicentre, case-control, diagnostic study
    • Abstract: Publication date: Available online 4 October 2019Source: The Lancet OncologyAuthor(s): Huiyan Luo, Guoliang Xu, Chaofeng Li, Longjun He, Linna Luo, Zixian Wang, Bingzhong Jing, Yishu Deng, Ying Jin, Yin Li, Bin Li, Wencheng Tan, Caisheng He, Sharvesh Raj Seeruttun, Qiubao Wu, Jun Huang, De-wang Huang, Bin Chen, Shao-bin Lin, Qin-ming ChenSummaryBackgroundUpper gastrointestinal cancers (including oesophageal cancer and gastric cancer) are the most common cancers worldwide. Artificial intelligence platforms using deep learning algorithms have made remarkable progress in medical imaging but their application in upper gastrointestinal cancers has been limited. We aimed to develop and validate the Gastrointestinal Artificial Intelligence Diagnostic System (GRAIDS) for the diagnosis of upper gastrointestinal cancers through analysis of imaging data from clinical endoscopies.MethodsThis multicentre, case-control, diagnostic study was done in six hospitals of different tiers (ie, municipal, provincial, and national) in China. The images of consecutive participants, aged 18 years or older, who had not had a previous endoscopy were retrieved from all participating hospitals. All patients with upper gastrointestinal cancer lesions (including oesophageal cancer and gastric cancer) that were histologically proven malignancies were eligible for this study. Only images with standard white light were deemed eligible. The images from Sun Yat-sen University Cancer Center were randomly assigned (8:1:1) to the training and intrinsic verification datasets for developing GRAIDS, and the internal validation dataset for evaluating the performance of GRAIDS. Its diagnostic performance was evaluated using an internal and prospective validation set from Sun Yat-sen University Cancer Center (a national hospital) and additional external validation sets from five primary care hospitals. The performance of GRAIDS was also compared with endoscopists with three degrees of expertise: expert, competent, and trainee. The diagnostic accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of GRAIDS and endoscopists for the identification of cancerous lesions were evaluated by calculating the 95% CIs using the Clopper-Pearson method.Findings1 036 496 endoscopy images from 84 424 individuals were used to develop and test GRAIDS. The diagnostic accuracy in identifying upper gastrointestinal cancers was 0·955 (95% CI 0·952–0·957) in the internal validation set, 0·927 (0·925–0·929) in the prospective set, and ranged from 0·915 (0·913–0·917) to 0·977 (0·977–0·978) in the five external validation sets. GRAIDS achieved diagnostic sensitivity similar to that of the expert endoscopist (0·942 [95% CI 0·924–0·957] vs 0·945 [0·927–0·959]; p=0·692) and superior sensitivity compared with competent (0·858 [0·832–0·880], p
       
  • Abemaciclib plus fulvestrant for breast cancer
    • Abstract: Publication date: Available online 3 October 2019Source: The Lancet OncologyAuthor(s): Robert Stirrups
       
  • Veliparib for advanced ovarian cancer
    • Abstract: Publication date: Available online 3 October 2019Source: The Lancet OncologyAuthor(s): Talha Khan Burki
       
  • Niraparib improves progression-free survival in ovarian cancer
    • Abstract: Publication date: Available online 3 October 2019Source: The Lancet OncologyAuthor(s): Elizabeth Gourd
       
  • European Society of Medical Oncology 2019 Congress
    • Abstract: Publication date: Available online 3 October 2019Source: The Lancet OncologyAuthor(s): Cheryl Lai
       
  • Untapped potential: recognising CNS opportunities in early oncology drug
           development
    • Abstract: Publication date: Available online 3 October 2019Source: The Lancet OncologyAuthor(s): Tejas Patil, D Ross Camidge
       
  • Improving care for the overlooked in oncology: incarcerated patients
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): Oluwadamilola T Oladeru, Subha Perni, Brie Williams
       
  • Correction to Lancet Oncol 2019; 20: 1252–62
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s):
       
  • Correction to Lancet Oncol 2019; 20: 1171–82
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s):
       
  • Correction to Lancet Oncol 2019; 20: 408–19
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s):
       
  • High Z nanoparticles and radiotherapy: a critical view – Authors'
           reply
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): Sylvie Bonvalot, Eva Wardelmann, Cécile Le Péchoux
       
  • High Z nanoparticles and radiotherapy: a critical view
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): Florent Vilotte, Raphael Jumeau, Jean Bourhis
       
  • Pazopanib for progressive desmoid tumours: children, persistant effects,
           and cost – Author's reply
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): Antoine Italiano
       
  • Pazopanib for progressive desmoid tumours: children, persistant effects,
           and cost
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): Yoshihiro Nishida, Tomohisa Sakai, Hiroshi Koike, Kan Ito
       
  • A critique of the fragility index – Authors' reply
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): Joseph C Del Paggio, Ian F Tannock
       
  • A critique of the fragility index
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): Tiago Machado, Gonçalo S Duarte, Nilza Gonçalves, Joaquim J Ferreira, João Costa
       
  • A critique of the fragility index
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): Alexandra Desnoyers, Michelle B Nadler, Brooke E Wilson, Eitan Amir
       
  • A critique of the fragility index
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): David Bomze, Tomer Meirson
       
  • Night shift work and its carcinogenicity
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): Yin Zhang, Kyriaki Papantoniou
       
  • Vaping-related lung illnesses: time to act
    • Abstract: Publication date: October 2019Source: The Lancet Oncology, Volume 20, Issue 10Author(s): The Lancet Oncology
       
  • Time-to-progression after front-line fludarabine, cyclophosphamide, and
           rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a
           retrospective, multicohort study
    • Abstract: Publication date: Available online 30 September 2019Source: The Lancet OncologyAuthor(s): Carmen D Herling, Kevin R Coombes, Axel Benner, Johannes Bloehdorn, Lynn L Barron, Zachary B Abrams, Tadeusz Majewski, Jolanta E Bondaruk, Jasmin Bahlo, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer, Bogdan A Czerniak, Christopher C Oakes, Alessandra Ferrajoli, Michael J Keating, Lynne V AbruzzoSummaryBackgroundFludarabine, cyclophosphamide, and rituximab (FCR) has become a gold-standard chemoimmunotherapy regimen for patients with chronic lymphocytic leukaemia. However, the question remains of how to treat treatment-naive patients with IGHV-unmutated chronic lymphocytic leukaemia. We therefore aimed to develop and validate a gene expression signature to identify which of these patients are likely to achieve durable remissions with FCR chemoimmunotherapy.MethodsWe did a retrospective cohort study in two cohorts of treatment-naive patients (aged ≥18 years) with chronic lymphocytic leukaemia. The discovery and training cohort consisted of peripheral blood samples collected from patients treated at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), who fulfilled the diagnostic criteria of the International Workshop on Chronic Lymphocytic Leukemia, had received at least three cycles of FCR chemoimmunotherapy, and had been treated between Oct 10, 2000, and Oct 26, 2006 (ie, the MDACC cohort). We did transcriptional profiling on samples obtained from the MDACC cohort to identify genes associated with time to progression. We did univariate Cox proportional hazards analyses and used significant genes to cluster IGHV-unmutated samples into two groups (intermediate prognosis and unfavourable prognosis). After using cross-validation to assess robustness, we applied the Lasso method to standardise the gene expression values to find a minimum gene signature. We validated this signature in an external cohort of treatment-naive patients with IGHV-unmutated chronic lymphocytic leukaemia enrolled on the CLL8 trial of the German Chronic Lymphocytic Leukaemia Study Group who were treated between July 21, 2003, and April 4, 2006 (ie, the CLL8 cohort).FindingsThe MDACC cohort consisted of 101 patients and the CLL8 cohort consisted of 109 patients. Using the MDACC cohort, we identified and developed a 17-gene expression signature that distinguished IGHV-unmutated patients who were likely to achieve a long-term remission following front-line FCR chemoimmunotherapy from those who might benefit from alternative front-line regimens (hazard ratio 3·83, 95% CI 1·94–7·59; p
       
  • Refining prognosis after first-line fludarabine, cyclophosphamide, and
           rituximab chemoimmunotherapy in chronic lymphocytic leukaemia
    • Abstract: Publication date: Available online 30 September 2019Source: The Lancet OncologyAuthor(s): Lukáš Smolej
       
  • Changes in e-cigarette policies worldwide
    • Abstract: Publication date: Available online 30 September 2019Source: The Lancet OncologyAuthor(s): Talha Khan Burki
       
  • Targeting lineage plasticity in prostate cancer
    • Abstract: Publication date: Available online 9 September 2019Source: The Lancet OncologyAuthor(s): Emmanuel S Antonarakis
       
  • CDK4/6 inhibitors: taking the place of chemotherapy'
    • Abstract: Publication date: Available online 4 September 2019Source: The Lancet OncologyAuthor(s): Azadeh Nasrazadani, Adam M Brufsky
       
  • Selinexor–dexamethasone for refractory multiple myeloma
    • Abstract: Publication date: Available online 30 August 2019Source: The Lancet OncologyAuthor(s): Robert Stirrups
       
  • Chemotherapy-free, but not quite free chemotherapy
    • Abstract: Publication date: Available online 29 August 2019Source: The Lancet OncologyAuthor(s): John O Schorge
       
  • Solid organ transplantations in childhood cancer survivors: an unrealised
           research potential
    • Abstract: Publication date: Available online 27 August 2019Source: The Lancet OncologyAuthor(s): Jeanette F Winther, Ida Maria Schmidt, Emilio D Poggio
       
  • Correction to Lancet Oncol 2019; published online Aug 16.
           http://dx.doi.org/10.1016/S1470-2045(19)30413-9
    • Abstract: Publication date: Available online 21 August 2019Source: The Lancet OncologyAuthor(s):
       
  • Renal cell carcinoma treatment after first-line combinations
    • Abstract: Publication date: Available online 16 August 2019Source: The Lancet OncologyAuthor(s): Camillo Porta, Manuela Schmidinger
       
  • Should we use combination therapy for all advanced renal cell
           carcinoma'
    • Abstract: Publication date: Available online 16 August 2019Source: The Lancet OncologyAuthor(s): Giuseppe Procopio, Pierangela Sepe, Melanie Claps, Filippo de Braud, Elena Verzoni
       
  • Immune checkpoint inhibitors: a game changer for metastatic non-small-cell
           lung cancer
    • Abstract: Publication date: Available online 14 August 2019Source: The Lancet OncologyAuthor(s): Pierre-Jean Souquet, Sébastien Couraud
       
  • Choosing surgery or radiotherapy for oropharyngeal squamous cell
           carcinoma: is the issue definitely settled'
    • Abstract: Publication date: Available online 12 August 2019Source: The Lancet OncologyAuthor(s): Vincent Grégoire, Piero Nicolai
       
  • A new screening tool for FGFR inhibitor treatment'
    • Abstract: Publication date: Available online 9 August 2019Source: The Lancet OncologyAuthor(s): Aung Naing
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-